

| | |
|-------------------------|---------------------------------------|
| Reference: | FOI.9321.22 |
| Subject: | Radium-223 molecular radiotherapy use |
| Date of Request: | 6 July 2022 |

Requested:

Question 1

Please complete the table below:

| | |
|--|--|
| Radium-223 dichloride service | |
| Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n) | |
| If yes, please list the indications for which it is used in your trust? | |

Question 2

Please detail the number of patients that are treated with radium-223 dichloride in your trust:

| | |
|---|--|
| Patient numbers | |
| Number of prostate cancer patients completing treatment with radium-223 dichloride per year | |
| Number of prostate cancer patients initiating radium-223 dichloride treatment per year | |
| What is the average number of cycles administered per patient in your service? | |
| What is the waiting time before patients can receive radium-223 dichloride? | |
| How many patients are initiated with cabazitaxel per year in your trust? | |

Question 3

In what department is molecular radiotherapy provided in your trust?

| Administration | Radium-223 dichloride | ¹⁷⁷Lutetium based radioligand therapy for neuroendocrine tumours |
|-----------------------|------------------------------|--|
| Nuclear Medicine | | |
| Medical Physics | | |
| Radiotherapy | | |
| Oncology | | |
| Urology | | |
| Other | | |
| N/A | | |

Question 4

What codes are associated with molecular radiotherapy administration in your trust?

| NHS codes | HRG | OPCS code |
|-----------------------|-----|-----------|
| Radium-223 dichloride | | |

Question 5

Please complete the table below:

| Who performs the administration of the treatment? | Radium-223 dichloride | ¹⁷⁷ Lutetium based radioligand therapy for neuroendocrine tumours |
|---|-----------------------|--|
| CNS | | |
| Technician | | |
| NM nurse | | |
| NM physicist | | |
| NM Consultant | | |
| Oncologist | | |
| Other (<i>please state</i>) | | |

Question 6

Who holds the ARSAC licence in your trust?

| Administration | (y/n) | Radium-223 dichloride | ¹⁷⁷ Lutetium based radioligand therapy for neuroendocrine tumours |
|--|-------|-----------------------|--|
| Nuclear Medicine consultant | | | |
| Clinical Oncologist | | | |
| Radiologist | | | |
| Other (<i>please state speciality</i>) | | | |

Question 7

Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?

| Radiation safety (y/n) | Conducted in-house (<i>If so, please provide the number of full-time equivalents providing these services in your centre</i>) | Outsourced |
|------------------------------------|--|------------|
| Radioactive Waste Adviser (RWA) | | |
| Radiation Protection Adviser (RPA) | | |

| | | |
|------------------------------|--|--|
| Medical Physics Expert (MPE) | | |
|------------------------------|--|--|

Question 8

Please complete the table below:

| Dosimetry | (y/n) | If yes, what is the schedule after each administration? | If yes, is this analysed in-house or outsourced? |
|--|--------------|--|---|
| Is dosimetry performed for radium-223 dichloride prostate cancer patients? | | | |

Response:

Hywel Dda University Health Board (UHB) regrets to inform you that it does not hold the information requested.

UHB patients requiring Radiology are referred to the ChemoCare Team in Swansea Bay University Health Board (SBUHB). Therefore, we recommend that you redirect your request to the Freedom of Information Team at SBUHB. The contact details are as follows:

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.